English
Home > Products > 100986-85-4

China 100986-85-4 Factory

We'll dedicate ourselves to offering our esteemed customers together with the most enthusiastically thoughtful solutions for 100986-85-4,CAS NO 100986-85-4,Levofloxacin Injection,Levofloxacin formulation, "Passion, Honesty, Sound service, Keen cooperation and Development" are our objectives. We have been here anticipating good friends all over the environment!
100986-85-4, Certainly, competitive price, suitable package and timely delivery might be assured as per customers' demands. We sincerely hope to build business relationship with you on the basis of mutual benefit and profit in the very near future. Warmly welcome to contact us and become our direct cooperators.

Related Products

Hot Products

  • 3-bromo-5-chloro-6-ethylpyrazine-2-carbonitrile

    3-bromo-5-chloro-6-ethylpyrazine-2-carbonitrile

    Product Name:3-bromo-5-chloro-6-ethylpyrazine-2-carbonitrile
    Molecular Formula:C7H5BrClN3
    Molecular Weight:246.49
    CAS Registry Number:2043020-03-5
  • 11-a-Hydroxy canrenone methyl ester

    11-a-Hydroxy canrenone methyl ester

    Product Name:11-a-Hydroxy canrenone methyl ester
    Molecular Formula:C24H32O6
    Molecular Weight:416.51
    CAS Registry Number:192704-56-6
  • Sugammadex sodium

    Sugammadex sodium

    Product Name:Sugammadex sodium
    Molecular Formula:C72H104Na8O48S8
    Molecular Weight;2177.97
    CAS Registry Number;343306-79-6
  • Alprostadil

    Alprostadil

    Product Name:Alprostadil
    Molecular Formula:C20H34O5
    Molecular Weight:354.49
    CAS Registry Number:745-65-3
  • Delafloxacin

    Delafloxacin

    Product Name:Delafloxacin
    Molecular Formula:C24H23F3N4O5
    Molecular Weight;504.46
    CAS Registry Number;442526-91-2
  • (+/-)-2-(6-METHOXY-2-NAPHTHYL)PROPIONIC ACID

    (+/-)-2-(6-METHOXY-2-NAPHTHYL)PROPIONIC ACID

    Product Name:(+/-)-2-(6-METHOXY-2-NAPHTHYL)PROPIONIC ACID
    Molecular Formula:C14H14O3
    Molecular Weight:230.26
    CAS Registry Number:23981-80-8
  • Related Blog
  • Reviews

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • What Is Ursodeoxycholic Acid Used For?

    Ursodeoxycholic acid is a cholelithiant commonly used in the gastroenterology department, and also a cholelithiasis dissolving agent, so it can be used in the treatment of gallstones under normal circumstances, on the premise...

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 100986-85-4CAS NO:100986-85-4

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept